$4.850
+0.123 (+2.54%)At close
- High
- 4.929
- Open
- 4.380
- VWAP
- 4.72
- Vol
- 56.95K
- Mkt Cap
- 192.46M
- Low
- 4.372
- Amount
- 268.63K
- EV/EBITDA, TTM
- 61.82
Genfit SA is a France-based biopharmaceutical company focused on the discovery and development of therapeutic and diagnostic solutions in the field of liver diseases, particularly of metabolic origin, where unmet medical needs are considerable, particularly due to a lack of approved treatments. The Company provides therapeutic and diagnostic solutions for rare and serious liver diseases , with a particular interest in diseases with largely unmet medical needs. Its laboratory capabilities include pharmacology, molecular and cellular biology, drug candidate screening, medicinal and analytical chemistry, biochemistry, omics analyses, and data science. Its in-house biobank allows to have unparalleled control and precision in the handling and preservation of biological samples, which is crucial to research. The Company leverage artificial intelligence (image processing tools and language models) to create tools that accelerate daily work and decision-making.
Valuation Metrics
Events Timeline
News
9.501-07GlobenewswireGENFIT Announces 2026 Financial Calendar Including Key Revenue Dates
9.001-06GlobenewswireGENFIT's G1090N Drug Candidate Shows Favorable Safety and Strong Anti-Inflammatory Activity
9.012-10GlobenewswireGENFIT's GNS561 Combination Therapy Shows Tumor Control Potential
5.011-28NASDAQ.COMGenfit Names Pejvack Motlagh as Chief Medical Officer
5.011-27GlobenewswireGENFIT Appoints New CMO to Drive Clinical Development Strategy
GNFT FAQ — answered by Alphio AI
Genfit SA is a France-based biopharmaceutical company focused on the discovery and development of therapeutic and diagnostic solutions in the field of liver diseases, particularly of metabolic origin, where unmet medical needs are considerable, particularly due to a lack of approved treatments. The Company provides therapeutic and diagnostic solutions for rare and serious liver diseases , with a particular interest in diseases with largely unmet medical needs. Its laboratory capabilities include pharmacology, molecular and cellular biology, drug candidate screening, medicinal and analytical chemistry, biochemistry, omics analyses, and data science. Its in-house biobank allows to have unparalleled control and precision in the handling and preservation of biological samples, which is crucial to research. The Company leverage artificial intelligence (image processing tools and language models) to create tools that accelerate daily work and decision-making. It operates in the Healthcare sector.
This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.